Phase II/III to evaluate the safety and efficacy of Thai Red Cross Society fibrin sealant compared with commercially available fibrin sealant (TISSEEL) in post-operative air leak. A randomized controlled trial

开始日期2024-11-01

申办/合作机构

Health Systems Research Institute

TCTR20240723010

/ Recruiting临床2/3期IIT

Phase II/III open-label randomized-controlled trial to evaluate the safety and efficacy of Fibrin sealant Thai Red Cross Society compared with commercially available fibrin sealant (TISSEEL) in pterygium volunteer

开始日期2024-10-09

申办/合作机构

Health Systems Research Institute

CTRI/2023/06/053870

/ Not yet recruiting临床2期IIT

Randomised controlled trial comparing the efficacy of autologous platelet rich fibrin therapy versus hydrocolloid gel dressing in chronic non-healing cutaneous ulcers, an open label study from Eastern India.

开始日期2023-06-30

申办/合作机构-

100 项与 Fibrin Sealant (Baxter) 相关的临床结果

登录后查看更多信息

100 项与 Fibrin Sealant (Baxter) 相关的转化医学

登录后查看更多信息

100 项与 Fibrin Sealant (Baxter) 相关的专利（医药）

登录后查看更多信息

570

项与 Fibrin Sealant (Baxter) 相关的文献（医药）

2025-04-01·Journal of Maxillofacial and Oral Surgery

Comparing the Efficacy of Tisseel versus Surgicel as a Hemostatic Agent in Cleft Palate Surgery: A Randomized Controlled Trial

Article

作者: Parameswaran, Anantanarayanan ; Ramanathan, Manikandan ; Madhumithra, K G

PurposeThe purpose of this randomized clinical trial is to compare the efficacy of Tisseel (fibrin glue) with Surgicel as a hemostatic agent in cleft palate surgery.MethodsThis prospective randomized clinical trial consists of 22 patients consenting to the study, and they were randomly allocated to Surgicel (Group 1) and Tisseel (fibrin glue-Group 2), with 11 patients in each. It was a parallel-group clinical trial with balanced randomization (1:1). Patients reported to Meenakshi cleft and craniofacial center for cleft palate surgery were included in this study. The primary outcome measures of this study were to assess the bleeding (intraoperative-bleeding scale) and healing in periodic intervals (healing chart).ResultsThis study includes 22 patients, of which 8 were bilateral cleft palate and 14 were unilateral cleft palate. The maximum width of the cleft at the level of hard and soft palate recorded was 1.5 cm and 1.8 cm, respectively. On comparing the bleeding scales among the two groups, the differences were said to be statistically significant (p = 0.011). There were 2 reported cases of palatal fistula in Surgicel group I in the 9th and 13th month of follow-up. Our study occurrence of palatal fistula ranged 4.5% in the Surgicel group and 0% in the Tisseel group.ConclusionBy comparing bleeding and wound healing in primary palate repair defects, the Tisseel group patients significantly showed better results compared to the Surgicel group. The tolerance to Tisseel was also evident by the way of reduced inflammation and less complications in that group.

2025-03-01·Veterinary Ophthalmology

Comparison of conjunctival pedicle flap to corneal fixation strength achieved by Tisseel® fibrin glue, ethyl cyanoacrylate adhesive, ReSure® hydrogel sealant, and conventional suturing with 8‐0 VICRYL® ophthalmic suture

Article

作者: Ramos, Renata Velloso ; Galarza, Roxanne M. Rodriguez ; Herring, Ian P. ; Kemper, Andrew R. ; VerHulst, Elodie M.

AbstractObjectiveTo determine and compare the fixation strength of conjunctival pedicle flaps to cornea achieved via conventional ophthalmic suture and three different adhesive compounds.Animals StudiedEx vivo porcine globes.ProceduresFollowing a 6 mm wide 500‐micron‐restricted depth lamellar keratectomy, conjunctival pedicle flaps were secured to the keratectomy site with either 8‐0 VICRYL® suture or one of three adhesive products, including Tisseel® bioadhesive, ReSure® synthetic adhesive, or ethyl cyanoacrylate adhesive (n = 10 per surgical group). Adhesive application protocol varied by product based upon adhesive biocompatibility. Corneoconjunctival tissues were then harvested, clamped in a tensile testing device, and loaded at a rate of 1 mm/s under video surveillance until the point of failure. Peak load was determined for each test and used to compare fixation strength between samples.ResultsForty conjunctival flaps were performed, with 6 omitted from evaluation due to dehiscence prior to tensile testing. Of the 34 flaps analyzed, 10 were secured with suture, 10 with cyanoacrylate, 8 with ReSure®, and 6 with Tisseel®. Flaps secured with suture withstood significantly higher applied tensile force compared with cyanoacrylate (p = .02474), ReSure® (p = .00000), and Tisseel® (p = .00002). Flaps secured with cyanoacrylate withstood significantly greater force than those secured with ReSure® and Tisseel® (p = .01194 and 0.01798, respectively). There was no significant difference in fixation strength between ReSure® and Tisseel® glue (p = .95675).ConclusionsConjunctival pedicle flap fixation using 8‐0 VICRYL® suture fixation was able to withstand significantly greater maximum tensile force compared to ReSure®, Tisseel®, or cyanoacrylate adhesives. Fixation strength achieved with cyanoacrylate adhesive was significantly greater than that achieved with ReSure® or Tisseel®.

2025-02-01·Clinical Neurology and Neurosurgery

Role of CT myelography in the diagnosis and management of spontaneous intracranial hypotension

Article

作者: Marc-Antoine, Migaud ; Simon, Henry

INTRODUCTIONSpontaneous intracranial hypotension (SIH) is a secondary cause of headache. Its pathophysiology is complex, and relies mainly on the notion of a localized leak, and thus a loss of cerebrospinal fluid (CSF) in the spinal region. SIH is little known to the medical profession, for which CT myelography is a technique on the rise, allowing to identify and treat the leak using a blood-patch or a fibrin sealant. The aim of the study was to investigate the contribution of CT myelography in the diagnostic and therapeutic management of spontaneous intracranial hypotension, its modalities and population characteristics.MATERIAL AND METHODSA cohort of patients with spontaneous intracranial hypotension who underwent a CT myelography in our department was retrospectively studied. Nineteen patients were included between March 2020 and October 2022.RESULTSCT myelography allowed identification of an etiology in 16 patients (84 %). The etiology of the leak was mainly a dural tear, identified in 11 patients. One diverticulum and 4 CSF-venous fistulas were identified. First targeted injection of fibrin sealant allowed stopped the leak in 12 out of 17 patients.CONCLUSIONCT myelography allows to identify the etiology of the CSF leak and pinpoint its topography. CT guidance can then be used to treat the leak in the same therapeutic timeframe, with greater efficacy during the first targeted injection of fibrin sealant. The current study data showed a high incidence of dural tears, and a significant proportion of venous-dural fistulas, and a low incidence of diverticulum.

项与 Fibrin Sealant (Baxter) 相关的新闻（医药）

2024-01-30

·BioSpace

RION Announces Initiation of Phase 2A Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers

RION's Phase 2A clinical trial focuses on evaluating the safety and efficacy of Platelet Exosome Product™ (PEP™) combined with TISSEEL fibrin sealant for treating Diabetic Foot Ulcers (DFU). Diabetic Foot Ulcers, affecting 18.6 million people worldwide each year, significantly impact quality of life and impose substantial economic burdens on healthcare systems. The trial is a key part of RION's broader efforts in regenerative medicine, aiming to address unmet needs in the treatment of chronic conditions such as DFU. ROCHESTER, Minn.--(BUSINESS WIRE)-- RION, a clinical-stage regenerative medicine company, at the forefront of the exosome therapeutic revolution, has officially commenced a Phase 2A study aimed at assessing the efficacy and safety of its exclusive exosome regenerative therapeutic, known as Purified Exosome Product™ (PEP™), for the management of Diabetic Foot Ulcers (DFU). This press release features multimedia. View the full release here: RION, located in Rochester, MN, is internationally recognized for its pioneering advancements in isolating and mass-producing platelet-derived exosomes. (Photo: Business Wire) Diabetic Foot Ulcers affect approximately 18.6 million people worldwide each year1 and are associated with increasing rates of amputation and death. The economic burden of DFUs is substantial, imposing $13 billion in cost on the US public and private healthcare systems.2 The trial is a key part of RION's broader efforts in regenerative medicine, aiming to address unmet needs in the treatment of chronic conditions such as DFU. Building on the success of the Phase 1B study conducted at Mayo Clinic, RION's Phase 2A trial represents a significant step forward in the development of a regenerative biologic for Diabetic Foot Ulcers. This prospective, randomized, multi-center study will involve 40 patients across the United States. Patients will be divided into two cohorts: one receiving standard care and the other treated with PEP™ exosomes, enabling a thorough comparison of outcomes. A positive outcome in the Phase 2A trial has the potential to pave the way for a pivotal study followed by the submission of a Biologics License Application (BLA). PEP™ addresses a significant unmet medical need in the realm of diabetic wound care. Dr. Atta Behfar, Co-founder of RION, said, “The progress we've made in advancing PEP™, reflects our deep commitment to developing powerful exosome therapies that unleash the body’s ability to heal from within. Not only will this study address a critical unmet need in chronic wound care, but it’s a pivotal moment for RION. We are disrupting the boundaries of exosome technology, to develop a new generation of therapies endowed with the potential to truly transform the way we treat complex and incurable diseases.” In the United States, the treatment of DFUs remains a significant challenge in the medical community, with no new biologics approved by the US FDA for diabetic wounds since the late 1990s3. RION is committed to bringing exosome-based therapies to patients as quickly and safely as possible to transform the management and outcomes of this devastating condition. About RION RION was born out of the Mayo Clinic after two decades of research and innovation at that institution. RION is located in Rochester, MN and is internationally recognized for its pioneering advancements in isolating and mass-producing platelet-derived regenerative exosomes into shelf stable PEP™. RION is rewriting the regenerative medicine playbook. Our cutting-edge proprietary biomanufacturing platform crafts the future of regenerative therapy, unlocking the potent secrets within these tiny cellular messengers. RION’s regenerative PEP™ technology will be integral to the therapeutic exosome revolution. About PEP™ RION's Purified Exosome Product™ (PEP™) is a shelf stable product in a lyophilized powder derived from human platelets that contains stabilized platelet-derived regenerative exosomes. PEP™ is an exosome therapeutic that is designed to promote cell growth and formation of new blood vessels, while also reducing inflammation and protecting cells. RION and its scientific collaborators have performed extensive research showing the potential of PEP™ to heal a wide array of damaged tissue. The company is currently evaluating PEP™ in preclinical and clinical studies for several indications. While our focus remains on wound healing, multiple IND-enabling efforts in musculoskeletal, cardiovascular disease, pulmonary disease and women’s health disorders are creating new solutions where current standards of care cannot address unmet clinical needs. About Diabetic Foot Ulcers (DFU) Diabetic foot ulcers (DFUs) are not just wounds. These slow-healing sores on the feet are a brutal consequence of diabetes, inflicting a triple threat: excruciating pain, crippling mobility, and the specter of amputation. The numbers paint a grim picture. Up to 25% of people with diabetes will face a DFU in their lifetime4, and for almost a quarter of them also limb amputation5. In fact, every three and a half minutes in the US, a DFU becomes an amputation6. This isn't just a statistic, it's a story of lives shattered, livelihoods lost, and families forever changed. Many patients endure the agony of recurrences, their lives trapped in a cycle of healing and reopening wounds. And sadly, the shadow of mortality looms large. 40% of DFU sufferers will succumb to the condition7, making it a pervasive silent killer of diabetic communities. The economic cost is equally staggering. DFUs drain healthcare systems, piling on direct treatment expenses and crippling indirect costs from lost productivity and long-term disability. RION's journey is paved with unwavering determination. We seek to break the cycle of pain, loss, and economic burden through application of our next-generation regenerative exosome technology. We will remain undeterred in our pursuit to have PEP™ become the first biologic to be approved for the treatment of DFU in over 25 years. References 1. Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic Foot Ulcers: A Review. JAMA. 2023 Jul 3;330(1):62-75. doi: 10.1001/jama.2023.10578. PMID: 37395769; PMCID: PMC10723802. 2. Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB. Burden of diabetic foot ulcers for medicare and private insurers. Diabetes Care. 2014;37(3):651-8. doi: 10.2337/dc13-2176. Epub 2013 Nov 1. Erratum in: Diabetes Care. 2014 Sep;37(9):2660. PMID: 24186882. 3. Fang RC, Galiano RD. A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers. Biologics. 2008 Mar;2(1):1-12. doi: 10.2147/btt.s1338. PMID: 19707423; PMCID: PMC2727777. 4. Yazdanpanah L, Shahbazian H, Nazari I, Arti HR, Ahmadi F, Mohammadianinejad SE, Cheraghian B, Hesam S. Incidence and Risk Factors of Diabetic Foot Ulcer: A Population-Based Diabetic Foot Cohort (ADFC Study)-Two-Year Follow-Up Study. Int J Endocrinol. 2018 Mar 15;2018:7631659. doi: 10.1155/2018/7631659. PMID: 29736169; PMCID: PMC5875034. 5. Liao X, Li SH, El Akkawi MM, Fu XB, Liu HW, Huang YS. Surgical amputation for patients with diabetic foot ulcers: A Chinese expert panel consensus treatment guide. Front Surg. 2022 Nov 8;9:1003339. doi: 10.3389/fsurg.2022.1003339. PMID: 36425891; PMCID: PMC9679004. 6. Amputation Prevention Alliance. (n.d.). Amputation prevention alliance. Amputation Prevention Alliance | ADA. 7. Jeyaraman K, Berhane T, Hamilton M, Chandra AP, Falhammar H. Mortality in patients with diabetic foot ulcer: a retrospective study of 513 cases from a single Centre in the Northern Territory of Australia. BMC Endocr Disord. 2019 Jan 3;19(1):1. doi: 10.1186/s12902-018-0327-2. PMID: 30606164; PMCID: PMC6318899.

临床2期上市批准

2022-06-11

·PRNewswire

At 8.6% CAGR, Global Tissue Sealants and Tissue Adhesive Market Size & Share to Surpass USD 2.9 Billion by 2028 | Industry Trends, Growth, Value, Opportunities, Statistics, Analysis & Forecast Report by ZMR

NEW YORK, June 11, 2022 /PRNewswire/ -- As per the Zion Market Research study, The global tissue sealants and tissue adhesive market was worth around USD 1.5 billion in 2021 and is estimated to grow to about USD 2.9 billion by 2028, with a compound annual growth rate (CAGR) of approximately 8.6 percent over the forecast period. The report analyzes the tissue sealants and tissue adhesive market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the tissue sealants and tissue adhesive market. Key Industry Insights &Findings of the Tissue Sealants and Tissue Adhesive Market Reports: As per the analysis shared by our research analyst, the Tissue Sealants and Tissue Adhesive Market is expected to grow annually at a CAGR of around 8.6% (2022-2028). Through the primary research, it was established that the Cognitive and Memory Enhancer Drugs Market was valued at approximately USD 1.5Billion in 2021 and is projected to reach roughly USD 2.9 Billion by 2028. Large population and technical advancements, North America accounted for the largest share of tissue sealants and tissue adhesive. State-of-the-art medical research facilities and rising investments in healthcare infrastructure in this region, and also heightened understanding among both physicians & patients relating to therapeutic approaches, enhanced life expectancy, and a rising population will push growing demands for tissue sealants and tissue adhesives in the Asia Pacific region. Zion Market Research published the latest report titled " Tissue Sealants And Tissue Adhesive Market By Product (Natural Or Biological Sealants & Adhesives And Synthetic & Semi-Synthetic Adhesives), By Application (General Surgery, Orthopedic Surgery, Gynecology Surgery, Cardiovascular Surgery, Cosmetic Surgery, Neurosurgery, And Other Applications), By End-User (Ambulatory Surgery Centers, Specialty Clinics, And Hospitals), And By Region – Global And Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2022 – 2028 "into their research database. Tissue Sealants and Tissue Adhesive Market: Overview Sealants are materials used by surgeon to heal tissue that has been injured by a surgery or injury. Skin, internal organs, and blood vessels are among the tissues that have been damaged. Sealants are used in combination with mechanical procedures like sutures and staples to assist minimize blood loss and avoiding leaks. Tissue adhesives are liquid monomers that, when exposed to a moist surface (skin), begin an exothermic reaction, transforming into a polymer that establishes a strong tissue connection. Get a Free Sample Report with All Related Graphs & Charts (with COVID 19 Impact Analysis): Our Free Sample Report Includes: 2022 Updated Report Introduction, Overview, and In-depth industry analysis COVID-19 Pandemic Outbreak Impact Analysis Included 166 + Pages Research Report (Inclusion of Updated Research) Provide Chapter-wise guidance on Request 2022 Updated Regional Analysis with Graphical Representation of Size, Share & Trends Includes an Updated List of tables & figures Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis Zion Market Research methodology Industry Dynamics: Tissue Sealants and Tissue Adhesive Market: Growth Drivers Increase in number of orthopedic and cardiovascular procedures to foster the market. Over the forecast period, rising cardiovascular and orthopedic surgeries are expected to drive revenue growth in the global tissue sealants and tissue adhesive market. The ease of availability of novel tissue adhesives and tissue sealants among end users, combined with rising disposable money, is a major driver in the global increase in such procedures. Adhesives are essential in general surgery. Natural and manufactured polymeric materials can be used to create three-dimensional networks that adhere to target tissues chemically and physically, acting as adhesives, sealants, or hemostats. Because adhesives and sealants are such an important aspect of general surgery, demand for them will rise as the number of procedures performed increases. As a result, market growth is likely to be boosted . Tissue Sealants and Tissue Adhesive Market: Restraints Less market penetration for tissue sealants and adhesives in developing countries hinders the growth. The market's growth is also likely to be hampered by the dearth of acceptance of tissue glue and bio-adhesive sealants in developing markets. This is due to a lack of knowledge about the advantages, cost-effectiveness, therapeutic application, and reliability of tissue adhesive and tissue sealants against alternative procedures or products, as well as tissue healing therapies. Directly Purchase a Copy of the Report @ Global Tissue Sealants and Tissue Adhesive Market: Opportunities Technological advancement for product launches creates numerous opportunities for market growth. Companies have been working on the development of novel tissue glue and bio-adhesive sealants to reach a variety of consumers, including toddlers, and young and elderly patients, during the last few years. Tissue sealants are currently used to protect sensitive, fragile, skin from damage, and to prevent cross-contamination & infection transmission. For innovative product launches, major companies are investing heavily in R&D activities. All such factors are likely to generate numerous opportunities for the global tissue sealants and tissue adhesive market growth during the forecast period. Global Tissue Sealants and Tissue Adhesive Market: Challenges Limitations in the development of tissue adhesive to act as a major challenge for the market growth. Despite the fact that many tissue adhesives form strong connections with tissue, they are frequently not designed for specific tissue applications. Tissue adhesives, in particular, do not biodegrade at a rate consistent with tissue repair, cause an unwanted inflammatory response upon adhesion or disintegration, fail to cohere in high-load-bearing applications, or do not match the characteristics of the underlying tissue. In the early stages of development, rigorous differentiation of target applications and greater in-depth investigation of tissue-surface features and tissue-environmental parameters are necessary. Despite the fact that the surface of the tissue and the surrounding environment change amongst tissues, the most typical technique is to utilize one type of adhesive for all conceivable tissues. This "one-size-fits-all" approach frequently results in tissue adhesive misuse, leading to inferior performance and dampening enthusiasm for potentially promising new materials. This could also lead to an incorrect cost-effectiveness analysis for specified unmet clinical requirements in the early stages of development, culminating in an exaggeration of cost in later stages of development and obstructing clinical translation. A failure to understand the physiological effects of adhesive materials after implantation is another factor for the research-to-product mismatch. All such limitations may pose challenges to market growth . Global Tissue Sealants and Tissue Adhesive Market: Segmentation The global tissue sealants and tissue adhesive market is categorized based on product, application, end-user, and region. Based on the product, the market is divided into semi-synthetic & synthetic adhesives and biological or natural sealants. The application segment consists of neurosurgery, cosmetic surgery, cardiovascular surgery, gynecology surgery, orthopedic surgery, general surgery, and other applications. The end-user segment is bifurcated into ambulatory surgery centers, specialty clinics, and hospitals. Get More Insight before [email protected]: List of Key Players inTissue Sealants and Tissue Adhesive Market: Integra LifeSciences C.R Bard Smith & Nephew Exapharma Johnson & Johnson Baxter International Inc. Tissuemed Ltd. Chemence Medical Inc. Cohera Medical Inc. Luna Innovations Incorporated Key questions answered in this report: What are the growth rate forecast and market size for Tissue Sealants and Tissue Adhesive Market? What are the key driving factors propelling the Tissue Sealants and Tissue Adhesive Market forward? What are the most important companies in the Tissue Sealants and Tissue Adhesive Market Industry? What segments does the Tissue Sealants and Tissue Adhesive Market cover? How can I receive a free copy of the Tissue Sealants and Tissue Adhesive Market sample report and company profiles? Report Scope: Free Brochure: Recent Developments: In January 2020, Polyganics, a medical technology business that develops, manufactures, and sells bioresorbable medical devices, revealed that LIQOSEAL®, its effortless and unique dural sealant patch, has received CE certification and will be available in Europe immediately. In December 2019, Johnson & Johnson Medical Devices Companies announced that Ethicon has released VISTASEAL Fibrin Sealant (Human) to assist surgeons minimize bleeding during surgery. VISTASEAL Fibrin Sealant (Human) is made up of fibrinogen and thrombin, which are both clotting proteins present in human plasma. It creates a fast, adherent, and permanent clot after placed on the bleeding site and has been shown to maintain hemostasis (blood stoppage) in high-risk patients. Regional Dominance: North America is the leader in the global market. Among the regions, North America is estimated to lead the global tissue sealants and tissue adhesive market during the forecast period. Because of its large population and technical advancements, North America accounted for the largest share of tissue sealants and tissue adhesive. However, the market for tissue sealants and tissue adhesives is expected to expand significantly in Asia Pacific countries. Factors such as state-of-the-art medical research facilities and rising investments in healthcare infrastructure in this region, and also heightened understanding among both physicians & patients relating therapeutic approaches, enhanced life expectancy, and a rising population will push growing demands for tissue sealants and tissue adhesives in Asia Pacific region. Global Tissue Sealants and Tissue Adhesive Market is segmented as follows: Tissue Sealants and Tissue Adhesive Market:ByProduct Outlook(2022-2028) Natural or Biological Sealants and Adhesives Synthetic and Semi-Synthetic Adhesives Tissue Sealants and Tissue Adhesive Market: By ApplicationOutlook (2022-2028) General Surgery Orthopedic Surgery Gynecology Surgery Cardiovascular Surgery Cosmetic Surgery Neurosurgery Other Applications Tissue Sealants and Tissue Adhesive Market: By End-user Outlook (2022-2028) Hospitals Specialty Clinics Ambulatory Surgery Centers Tissue Sealants and Tissue Adhesive Market:By Region Outlook(2022-2028) North America The U.S. Canada Europe France The UK Spain Germany Italy Rest of Europe Asia Pacific China Japan India South Korea Southeast Asia Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa GCC South Africa Rest of Middle East & Africa Browse Other Related Research Reports from Zion Market Research Orthopedic Navigation Systems Market - Global Industry Analysis : The global Orthopedic Navigation Systems market accrued earnings worth approximately 2.1(USD Billion) in 2020 and is predicted to gain revenue of about 7.3 (USD Billion) by 2028, is set to record a CAGR of nearly 14.7% over the period from 2021 to 2028. Intravenous Infusion Pumps Market - Global Industry Analysis : The global Intravenous Infusion Pumps market accrued earnings worth approximately 4.7 (USD Billion) in 2020 and is predicted to gain revenue of about 8.9 (USD Billion) by 2028, is set to record a CAGR of nearly 8.1% over the period from 2021 to 2028. Disposable Hospital Gowns Market - Global Industry Analysis : The global Disposable Hospital Gowns market accrued earnings worth approximately 2.02 (USD Billion) in 2020 and is predicted to gain revenue of about 5.72 (USD Billion) by 2028, is set to record a CAGR of nearly 13.8% over the period from 2021 to 2028. Browse through Zion Market Research's coverage of the Global Medical Device Industry Follow Us on: LinkedIn | Twitter | Facebook About Us Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, and company reports to country report. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client's needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us . Contact Us: Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: [email protected] Website: Blog - Logo: SOURCE Zion Market Research

100 项与 Fibrin Sealant (Baxter) 相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
出血	美国	Baxter Healthcare Corp.	2000-02-07

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
出血	药物发现	德国	Baxter Innovations GmbH	2010-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02891070 (CTgov)	临床3期	脑脊液漏	224	Tisseel (Tisseel)	製鏇襯襯觸衊鑰繭艱膚(夢鹹網齋選製餘衊簾鏇) = 遞窪範鑰簾鬱築繭願糧壓衊艱淵製製鏇鑰獵襯 (願醖餘構窪網鏇醖齋觸, 衊壓選襯繭淵壓簾膚築 ~ 鏇糧願鹽憲願願壓築醖) 更多	-	2019-09-10
				Sealant (DuraSeal)	製鏇襯襯觸衊鑰繭艱膚(夢鹹網齋選製餘衊簾鏇) = 選範積窪蓋蓋憲糧遞窪壓衊艱淵製製鏇鑰獵襯 (願醖餘構窪網鏇醖齋觸, 築齋廠選觸製齋構遞餘 ~ 製膚範積鏇窪遞壓鹹獵) 更多
NCT01613664 (Pubmed \| Ann Surg)	临床3期	-	586	Fibrin Sealant	糧糧鑰顧觸鹽膚顧醖廠(築艱構蓋顧鬱齋鹹膚築) = 顧觸襯鏇選範鏇餘淵網憲壓鑰遞夢構鏇獵鬱襯 (蓋衊製艱鏇廠積壓齋鏇 ) 更多	-	2018-11-01
				Fibrin Sealant (Control (without FS))	糧糧鑰顧觸鹽膚顧醖廠(築艱構蓋顧鬱齋鹹膚築) = 衊顧鑰夢齋願繭夢淵糧憲壓鑰遞夢構鏇獵鬱襯 (蓋衊製艱鏇廠積壓齋鏇 ) 更多
ARVO2013	N/A	翼状胬肉	96	Evicel	(簾鏇襯淵鏇鏇繭醖觸壓) = 顧廠鹹觸獵獵積願製壓膚艱築蓋繭願齋艱醖構 (選鏇範壓願廠廠繭鬱窪 ) 更多	积极	2013-06-01
				Tisseel	(簾鏇襯淵鏇鏇繭醖觸壓) = 憲餘觸觸蓋醖願壓選膚膚艱築蓋繭願齋艱醖構 (選鏇範壓願廠廠繭鬱窪 ) 更多
NCT01244425 (CTgov)	临床2期	出血	70	Fibrin Sealant (FS) VH S/D 500 s-apr (FS VH S/D 500 S-apr)	醖衊鏇顧鹹鏇夢積鑰選(遞獵網鑰鑰製餘製構醖) = 構醖積願鏇廠糧鹽鹹齋繭簾獵齋築鏇製窪艱夢 (鏇蓋鏇淵顧淵夢遞願壓, 網鏇廠窪選鹽壓鏇顧觸 ~ 獵鬱憲醖鑰遞淵繭觸憲) 更多	-	2013-02-12
				Manual compression (Manual Compression - Control)	醖衊鏇顧鹹鏇夢積鑰選(遞獵網鑰鑰製餘製構醖) = 鹹鹹鏇餘醖齋餘醖築糧繭簾獵齋築鏇製窪艱夢 (鏇蓋鏇淵顧淵夢遞願壓, 蓋製積範衊衊遞齋構廠 ~ 憲築獵鬱製襯築積壓憲) 更多
NCT00324272 (CTgov)	临床4期	黑色素瘤 \| 鳞状细胞癌	74	Fibrin Sealant (Tisseel) used in the Experimental Arm. (Groin Dissection: Sealant Used.)	鬱憲鏇鏇餘鹽構壓鹹鹹(範淵衊膚蓋鏇製衊廠觸) = 憲襯衊繭遞簾網糧鹹構觸鏇鏇廠鑰鏇窪憲積範 (鑰蓋鑰餘壓鑰糧襯遞簾, 艱壓獵網築淵夢憲鑰鹽 ~ 積獵壓顧鹽範觸積積鏇) 更多	-	2011-08-11
				Fibrin Sealant (Tisseel) used in the Experimental Arm. (Groin Dissection: no Sealant Used.)	鬱憲鏇鏇餘鹽構壓鹹鹹(範淵衊膚蓋鏇製衊廠觸) = 鹹醖網壓繭築壓積網積觸鏇鏇廠鑰鏇窪憲積範 (鑰蓋鑰餘壓鑰糧襯遞簾, 築顧願繭襯鑰餘醖齋繭 ~ 艱齋構鹹觸襯築遞製襯) 更多
PO491 (AAO2008)	N/A	结膜疾病	60	Fibrin sealant	(蓋簾繭範醖衊積積鹹構) = 糧築醖廠簾衊鏇蓋構壓築憲構膚積淵築餘鹽鑰 (鑰繭遞廠築願願糧願襯 ) 更多	积极	2008-11-10
				Fibrin Sealant	(蓋簾繭範醖衊積積鹹構) = 淵網淵餘範積範餘壓鹹築憲構膚積淵築餘鹽鑰 (鑰繭遞廠築願願糧願襯 ) 更多
AAO2008	N/A	翼状胬肉	192	Tisseel	(淵範築淵網構積窪醖鏇) = 蓋顧構憲蓋積艱鹽憲遞獵廠窪簾夢遞襯夢窪蓋 (淵簾築蓋選範蓋鹹鏇襯 )	积极	2008-11-09
Gynecologic Oncology Group study (Pubmed \| Gynecol Oncol)	临床3期	淋巴水肿	150	VH fibrin sealant (Sutured closure)	淵鹽窪網鑰鏇製窪獵糧(範選遞鹹醖淵憲夢淵糧) = 膚襯網遞廠遞夢鏇鹽憲夢鹹遞獵膚鏇鑰膚憲衊 (簾壓窪鏇鏇膚鏇築艱願 ) 更多	不佳	2008-07-01
NCT00506311 (Pubmed \| World J Surg Oncol)	N/A	黑色素瘤	30	Fibrin sealant	簾獵窪夢願鑰構選衊簾(鹹膚鑰鏇鬱遞憲遞簾糧) = 顧鏇構鹹憲繭憲壓構蓋繭艱膚構壓網繭廠膚鹽 (衊壓繭獵艱憲艱鏇淵壓 )	不佳	2008-06-18
				Fibrin sealant (Control group)	簾獵窪夢願鑰構選衊簾(鹹膚鑰鏇鬱遞憲遞簾糧) = 獵膚憲襯艱齋構壓鹽網繭艱膚構壓網繭廠膚鹽 (衊壓繭獵艱憲艱鏇淵壓 )